Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free QLGN Stock Alerts

Qualigen Therapeutics (QLGN) Competitors

Qualigen Therapeutics logo
$1.02 0.00 (0.00%)
As of 07/10/2026
Compare

QLGN vs. OBSV, NKGN, ATON, ERNA, and CURX

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include ObsEva (OBSV), NKGen Biotech (NKGN), Portage Biotech (ATON), Ernexa Therapeutics (ERNA), and Curanex Pharmaceuticals (CURX). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to ObsEva?

Qualigen Therapeutics (NASDAQ:QLGN) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Qualigen Therapeutics' return on equity of 0.00% beat ObsEva's return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
ObsEva N/A -416.36%-92.01%

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
ObsEvaN/AN/A-$58.38M-$0.92N/A

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Given ObsEva's higher possible upside, analysts clearly believe ObsEva is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ObsEva
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company Overall Sentiment
Qualigen Therapeutics Neutral
ObsEva Neutral

Summary

ObsEva beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Qualigen Therapeutics Neutral

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Qualigen Therapeutics N/A N/A -202.16%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NKGen Biotech has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Summary

NKGen Biotech beats Qualigen Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Portage Biotech?

Portage Biotech (NASDAQ:ATON) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Portage BiotechN/AN/A-$6.77M-$8.18N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

Portage Biotech has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Portage Biotech presently has a consensus target price of $2.00, indicating a potential upside of 502.41%. Given Portage Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Portage Biotech is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Portage Biotech
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Portage Biotech's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company Overall Sentiment
Portage Biotech Neutral
Qualigen Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Portage BiotechN/A N/A N/A
Qualigen Therapeutics N/A N/A -202.16%

Summary

Portage Biotech beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Ernexa Therapeutics?

Qualigen Therapeutics (NASDAQ:QLGN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Ernexa Therapeutics has a consensus price target of $30.00, indicating a potential upside of 395.05%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Ernexa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Qualigen Therapeutics has higher earnings, but lower revenue than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A
Ernexa Therapeutics$580K12.22-$14.08M-$26.20N/A

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for Qualigen Therapeutics. Ernexa Therapeutics' average media sentiment score of 1.89 beat Qualigen Therapeutics' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Ernexa Therapeutics Very Positive

Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

Qualigen Therapeutics' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A N/A -202.16%
Ernexa Therapeutics N/A -263.74%-151.16%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ernexa Therapeutics beats Qualigen Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Curanex Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/A-$4.22M-$0.27N/A
Qualigen TherapeuticsN/AN/A-$6.26M-$7.50N/A

In the previous week, Curanex Pharmaceuticals had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 2 mentions for Curanex Pharmaceuticals and 0 mentions for Qualigen Therapeutics. Curanex Pharmaceuticals' average media sentiment score of 1.44 beat Qualigen Therapeutics' score of 0.00 indicating that Curanex Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Curanex Pharmaceuticals Positive
Qualigen Therapeutics Neutral

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 39.7% of Curanex Pharmaceuticals shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Qualigen Therapeutics' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A -85.41% -82.11%
Qualigen Therapeutics N/A N/A -202.16%

Summary

Curanex Pharmaceuticals beats Qualigen Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QLGN vs. The Competition

Export
MetricQualigen TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.73M$3.07B$7.09B$12.66B
Dividend YieldN/A2.06%2.68%8.00%
P/E Ratio-0.1420.0227.4224.53
Price / SalesN/A365.73528.3396.17
Price / CashN/A57.1148.4760.03
Price / Book-0.254.2910.886.38
Net Income-$6.26M$64.65M$3.59B$331.87M
7 Day Performance-7.27%-0.75%-0.26%0.37%
1 Month Performance-21.54%4.54%4.55%0.59%
1 Year Performance-70.18%24.67%29.86%22.26%

Qualigen Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QLGN
Qualigen Therapeutics
N/A$1.02
flat		N/A-70.2%$1.73MN/AN/A50
OBSV
ObsEva
N/AN/AN/AN/A$7.94MN/AN/A50
NKGN
NKGen Biotech
N/A$0.06
flat		N/AN/A$7.84MN/AN/AN/A
ATON
Portage Biotech
N/A$0.33
+3.8%		$2.00
+502.4%		N/A$7.78MN/AN/A6
ERNA
Ernexa Therapeutics
3.8501 of 5 stars		$6.70
+0.8%		$30.00
+347.8%		-87.6%$7.76M$580KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 7/12/2026 by MarketBeat.com Staff.
From Our Partners
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Buy the “unseen winner of the AI race” before July 22
Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...
Chaikin Analytics | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Elon’s New Currency (BUY NOW)
Elon Musk is reportedly launching a currency system that analysts say could target a $480 trillion market disr...
InvestorPlace | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel